期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 18, 期 7, 页码 -出版社
MDPI
DOI: 10.3390/ijms18071450
关键词
mesenchymal stem/stromal cells; cell therapy; extracellular vesicles; exosomes; microvesicles; immunomodulation
资金
- Medical Faculty of the University of Duisburg-Essen (IFORES)
- Volkswagen Foundation
- Stem Cell Network North Rhine Westphalia
- LeitmarktAgentur
- European Union for the EU program ME-HaD (COST Action) [BM1202]
Extracellular vesicles (EVs), such as exosomes and microvesicles, have been identified as mediators of a newly-discovered intercellular communication system. They are essential signaling mediators in various physiological and pathophysiological processes. Depending on their origin, they fulfill different functions. EVs of mesenchymal stem/stromal cells (MSCs) have been found to promote comparable therapeutic activities as MSCs themselves. In a variety of in vivo models, it has been observed that they suppress pro-inflammatory processes and reduce oxidative stress and fibrosis. By switching pro-inflammatory into tolerogenic immune responses, MSC-EVs very likely promote tissue regeneration by creating a pro-regenerative environment allowing endogenous stem and progenitor cells to successfully repair affected tissues. Accordingly, MSC-EVs provide a novel, very promising therapeutic agent, which has already been successfully applied to humans. However, the MSC-EV production process has not been standardized, yet. Indeed, a collection of different protocols has been used for the MSC-EV production, characterization and application. By focusing on kidney, heart, liver and brain injuries, we have reviewed the major outcomes of published MSC-EV in vivo studies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据